Employee Lawsuit Withdrawn, But Burrill Faces New Investor Claims
This article was originally published in Scrip
A lawsuit filed by an employee who oversaw venture capital funds run by Steven Burrill has been dismissed, but a separate lawsuit filed against Burrill, a prominent San Francisco-based advisor to life science companies, has been amended with new accusations against the fund's auditor, PricewaterhouseCoopers (PwC).
You may also be interested in...
A federal grand jury indicted Steven Burrill and an associate on charges of fraud and tax evasion regarding investment funds run by the San Francisco-based life science advisor, who settled a related SEC claim in 2016. If convicted, he could spend decades in prison and pay millions in fines.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.